Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (+)-Pentazocine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 10/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 4/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 3/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 3/20 | 1.00 |
| ▸ | EBP | Q15125 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.78 |
| ▸ | TSHR | P16473 | 1/20 | 0.78 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pentazocine SCHEMBL2493 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1TMEM97OPRD1OPRK1 | |
| (+)-Pentazocine SCHEMBL30132413 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1TMEM97OPRD1OPRK1 | |
| (+)-Pentazocine SCHEMBL2492 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1TMEM97OPRD1OPRK1 | |
| Rel-Pentazocine SCHEMBL135685 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1TMEM97OPRD1OPRK1 | |
| (+)-Pentazocine SCHEMBL16220021 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1TMEM97OPRD1OPRK1 | |
| (+)-Pentazocine SCHEMBL18672553 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1TMEM97OPRD1OPRK1 | |
| (+)-Pentazocine SCHEMBL4376337 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1TMEM97OPRD1OPRK1 | |
| (+)-Pentazocine SCHEMBL680675 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1TMEM97OPRD1OPRK1 | |
| (+)-Pentazocine SCHEMBL22865258 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1TMEM97OPRD1OPRK1 | |
| Pentazocine SCHEMBL29611805 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1TMEM97OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180185355-A1 | Method of Treating Dyskinesia | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2018-07-05 | — | — | US | disclosed |
| US-9918980-B2 | Method of treating dyskinesia | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2018-03-20 | — | — | US | disclosed |
| US-9918980-B2 | Method of treating dyskinesia | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2018-03-20 | — | — | US | disclosed |
| US-20180071390-A1 | COMPOSITIONS OF PHARMACEUTICAL ACTIVES CONTAINING DIETHYLENE GLYCOL MONOETHYL ETHER OR OTHER ALKYL DERIVATIVES | THEMIS MEDICARE LIMITED (IN) | 2018-03-15 | — | — | US | disclosed |
| US-9827315-B2 | Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives | THEMIS MEDICARE LIMITED (IN) | 2017-11-28 | — | — | US | disclosed |
| US-20160151359-A1 | Method of Treating Dyskinesia | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2016-06-02 | — | — | US | disclosed |
| US-20140296191-A1 | COMPOSITIONS OF PHARMACEUTICAL ACTIVES CONTAINING DIETHYLENE GLYCOL MONOETHYL ETHER OR OTHER ALKYL DERIVATIVES | THEMIS MEDICARE LIMITED (IN) | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071390-A1 | COMPOSITIONS OF PHARMACEUTICAL ACTIVES CONTAINING DIETHYLENE GLYCOL MONOETHYL ETHER OR OTHER ALKYL DERIVATIVES | DSG1, DEGS1, PLA2G2E | SIGMAR1 2521/4885OPRM1 3170/4885TMEM97 2719/4885 |
| US-20160151359-A1 | Method of Treating Dyskinesia | OPRK1, OPRM1, OPRD1 | SIGMAR1 5/4885OPRM1 2/4885TMEM97 148/4885 |
| US-20180185355-A1 | Method of Treating Dyskinesia | OPRM1, OPRD1, OPRK1 | SIGMAR1 5/4885OPRM1 1/4885TMEM97 217/4885 |
| US-20140296191-A1 | COMPOSITIONS OF PHARMACEUTICAL ACTIVES CONTAINING DIETHYLENE GLYCOL MONOETHYL ETHER OR OTHER ALKYL DERIVATIVES | DSG1, DEGS1, PLA2G2E | SIGMAR1 2521/4885OPRM1 3170/4885TMEM97 2719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.